Cite
APA Citation
Ahluwalia, M., Grabowski, M., Alban, T., Otvos, B., Bayik, D., Saeed Bamashmos, A., Rayman, P., Diaz-Montero, M., Reardon, D., Wen, P., Peereboom, D., & Lathia, J. (n.d.). aTIM-40. CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS PREDICT FAVORABLE RESPONSE TO IMMUNE CHECKPOINT THERAPY IN A RANDOMIZED TRIAL OF NIVOLUMAB AND BEVACIZUMAB IN RECURRENT GBM. Neuro-oncology, 21, vi10. http://access.bl.uk/ark:/81055/vdc_100101669209.0x000044